Prescription-only medicine

Editorially reviewed · Last updated February 2026 · How we review

Part of Weight Loss Drug Comparison Index.

Orforglipron vs Tirzepatide (Zepbound): Oral Pill vs Weekly Injection

Orforglipron and tirzepatide are both made by Eli Lilly, but they represent fundamentally different approaches to weight loss treatment. Orforglipron is a once-daily oral pill that targets the GLP-1 receptor only. Tirzepatide (sold as Zepbound for obesity and Mounjaro for diabetes) is a once-weekly injection that targets both GLP-1 and GIP receptors.

The trade-off is straightforward: tirzepatide produces nearly twice the weight loss (-22.5% vs -12.4%), but orforglipron eliminates the injection barrier entirely — no needles, no refrigeration, no injection site reactions. Both drugs are part of Lilly's strategy to cover the full spectrum of obesity treatment, from convenient first-line oral therapy to maximum-efficacy injectable options.

Side-by-Side Comparison

	Orforglipron	Tirzepatide (Zepbound)
Developer	Eli Lilly	Eli Lilly
Delivery	Once-daily oral pill	Once-weekly injection
Molecule type	Non-peptide small molecule	Peptide
Receptors	GLP-1 only (single agonist)	GLP-1 + GIP (dual agonist)
Max weight loss	-12.4% at 72 weeks (ATTAIN-1)	-22.5% at 72 weeks (SURMOUNT-1)
Max dose	36 mg daily	15 mg weekly
Food restrictions	None	None (injectable)
FDA status	Filed, decision expected Q2 2026	Approved (Zepbound 2023, Mounjaro 2022)
Key advantage	No injections, daily pill	Nearly 2x the weight loss

How the Mechanisms Differ

Orforglipron: One Receptor, Oral Delivery

Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike every injectable GLP-1 drug on the market — which are peptides that get destroyed by stomach acid — orforglipron is a small molecule that survives the gastrointestinal tract and can be taken as a pill.

It exhibits biased agonism, favoring G-protein signaling (the therapeutic pathway) over beta-arrestin recruitment (which leads to receptor downregulation). This means it activates the beneficial downstream effects — appetite suppression, insulin secretion, slowed gastric emptying — while potentially causing less receptor desensitization over time.

Because orforglipron targets only the GLP-1 receptor, its weight loss ceiling is limited compared to multi-receptor drugs. But it offers something no injectable can: true oral convenience with no fasting or food restrictions.

Tirzepatide: Two Receptors, Maximum Proven Efficacy

Tirzepatide activates both GLP-1 and GIP receptors simultaneously. The GLP-1 component handles appetite suppression and glucose control. The GIP (glucose-dependent insulinotropic polypeptide) component adds insulin sensitivity benefits and appears to enhance weight loss beyond what GLP-1 alone can achieve.

This dual mechanism is why tirzepatide produces roughly 22% weight loss — well beyond the 12-17% range typical of GLP-1-only drugs like semaglutide and orforglipron. Tirzepatide was the first obesity drug to demonstrate over 20% average weight loss in a Phase 3 trial.

Weight Loss Comparison

Phase 3 Trial Results

Drug	Trial	Duration	Max Weight Loss	Participants
Orforglipron 36 mg	ATTAIN-1 (Phase 3)	72 weeks	-12.4%	1,686
Orforglipron 12 mg	ATTAIN-1 (Phase 3)	72 weeks	-9.4%	1,686
Tirzepatide 15 mg	SURMOUNT-1 (Phase 3)	72 weeks	-22.5%	2,539
Tirzepatide 10 mg	SURMOUNT-1 (Phase 3)	72 weeks	-21.4%	2,539
Tirzepatide 5 mg	SURMOUNT-1 (Phase 3)	72 weeks	-16.0%	2,539

Even tirzepatide's lowest dose (5 mg) produced more weight loss than orforglipron's highest dose (36 mg). The gap is consistent and significant — tirzepatide's dual receptor mechanism drives substantially more weight reduction.

Weight Loss Thresholds

Threshold	Orforglipron 36 mg (ATTAIN-1)	Tirzepatide 15 mg (SURMOUNT-1)
Lost at least 5%	79.0%	91%
Lost at least 10%	59.6%	81%
Lost at least 15%	39.6%	62%
Lost at least 20%	—	40%

Important Caveats

These results come from different trials with different patient populations. ATTAIN-1 enrolled 1,686 adults with obesity or overweight (BMI 27+). SURMOUNT-1 enrolled 2,539 adults with obesity (BMI 30+) or overweight with comorbidities. Baseline characteristics differed between the two studies, so this is a cross-trial comparison rather than a head-to-head result.

Side Effects Comparison

	Orforglipron 36 mg (ATTAIN-1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	38.8%	33%
Diarrhea	22.4%	21%
Vomiting	18.5%	10%
Constipation	13.4%	11%
Severity	Mostly mild-moderate	Mostly mild-moderate
Discontinuation (GI)	5.3-10.3%	4.3-7.1%
Injection site reactions	N/A (oral)	Present

Both drugs share the standard GLP-1 gastrointestinal side effect profile. Orforglipron has somewhat higher rates of nausea and vomiting, possibly because daily oral dosing means daily GI exposure rather than weekly peaks. However, orforglipron's Phase 3 data showed no signals for pancreatitis, retinal detachment, or ischemic optic neuropathy.

Tirzepatide's advantage is that injection site reactions are typically mild, and weekly dosing means GI side effects are concentrated around dose escalation periods. Both drugs see the most GI complaints during the initial titration phase, with symptoms improving over time.

Convenience vs Efficacy: The Core Trade-Off

This comparison comes down to a fundamental decision: maximum convenience or maximum weight loss.

The Case for Orforglipron

No needles — a daily pill, taken any time of day
No food restrictions — unlike oral semaglutide (Rybelsus), which requires 30 minutes of fasting
No refrigeration — small-molecule pills are shelf-stable
Lower barrier to starting — many patients avoid injectable treatments due to needle phobia
Easier prescribing — primary care physicians may be more comfortable prescribing a pill than teaching injection technique
Potentially lower cost — small molecules are cheaper to manufacture than injectable peptides

The Case for Tirzepatide

Nearly 2x the weight loss — 22.5% vs 12.4%
Once-weekly dosing — one injection per week vs a pill every day
Proven track record — FDA-approved since 2022 (Mounjaro) and 2023 (Zepbound), with extensive real-world data
Better responder rates — 62% of patients lost 15% or more, compared to 40% on orforglipron
Cardiovascular outcomes data — the SURPASS-CVOT trial showed a 10% reduction in major adverse cardiovascular events

Who Might Choose Which?

Orforglipron first-line: Patients who refuse or cannot tolerate injections, those with moderate obesity who need 10-12% weight loss, patients who want a convenient daily pill
Tirzepatide first-line: Patients with severe obesity who need more than 15% weight loss, those comfortable with weekly injections, patients with type 2 diabetes (where tirzepatide has strong glycemic control data)
Step-up approach: Start with orforglipron for convenience, then switch to tirzepatide if more weight loss is needed

Switching Between the Two

Lilly's ATTAIN-MAINTAIN trial studied what happens when patients switch from injectable incretins to oral orforglipron. The results showed that patients switching from tirzepatide to orforglipron maintained most of their prior weight loss, with an average difference of only 5.0 kg over 52 weeks.

This suggests a practical clinical pathway: patients could use tirzepatide to achieve significant weight loss, then transition to orforglipron for long-term maintenance if they prefer an oral option. However, the 5 kg gap indicates some weight regain is likely when moving from a dual agonist to a single agonist.

Lilly's Portfolio Strategy

Eli Lilly is the only pharmaceutical company developing both an oral and injectable next-generation weight loss drug. Their portfolio strategy positions each drug for a different patient need:

Orforglipron — oral first-line therapy for accessibility, convenience, and patients who are needle-averse. Analysts project $16 billion in annual sales by 2031.
Tirzepatide (Zepbound/Mounjaro) — established injectable for maximum proven efficacy. Already generating over $10 billion in annual revenue.
Retatrutide — investigational triple agonist (GLP-1 + GIP + glucagon) for maximum weight loss. Phase 3 TRIUMPH-4 data showed -28.7% weight loss at 68 weeks, exceeding tirzepatide.

These drugs are complementary, not competing. Lilly envisions a treatment spectrum where physicians can match the right drug to the right patient based on their goals, preferences, and severity of obesity.

Where Retatrutide Fits

For context, Lilly's investigational triple agonist retatrutide exceeds both orforglipron and tirzepatide:

Drug	Receptors	Max Weight Loss	Trial
Orforglipron 36 mg	GLP-1	-12.4% (72 wks)	ATTAIN-1
Tirzepatide 15 mg	GLP-1 + GIP	-22.5% (72 wks)	SURMOUNT-1
Retatrutide 12 mg	GLP-1 + GIP + Glucagon	-28.7% (68 wks)	TRIUMPH-4

The pattern is consistent: more receptor targets correlate with greater weight loss. Retatrutide's glucagon receptor component adds energy expenditure on top of appetite suppression, pushing weight loss beyond what even dual agonists achieve. Lilly's direct head-to-head trial of retatrutide vs tirzepatide (TRIUMPH-5, active not recruiting) has primary completion in December 2026, with results expected to follow in 2027.

For detailed comparisons, see Retatrutide vs Tirzepatide and Retatrutide vs Orforglipron.

Frequently Asked Questions

Is orforglipron as effective as tirzepatide for weight loss?

No. Tirzepatide produces nearly twice the weight loss (-22.5%) compared to orforglipron (-12.4%) in Phase 3 trials. Tirzepatide's dual receptor mechanism (GLP-1 + GIP) drives substantially more weight reduction than orforglipron's single receptor (GLP-1 only). The trade-off is that orforglipron is an oral pill while tirzepatide requires weekly injections.

Can I take orforglipron instead of Zepbound?

If approved, orforglipron could be an alternative for patients who prefer a daily pill over a weekly injection. However, it produces less weight loss. The ATTAIN-MAINTAIN trial showed that switching from tirzepatide to orforglipron is feasible, though patients may regain some weight. Discuss options with your healthcare provider.

Are orforglipron and tirzepatide made by the same company?

Yes. Both are made by Eli Lilly. Orforglipron is Lilly's oral GLP-1 pill (filed for FDA approval, decision expected Q2 2026). Tirzepatide is Lilly's approved injectable dual agonist, sold as Zepbound for obesity and Mounjaro for type 2 diabetes. Lilly is also developing retatrutide, a triple agonist injectable.

Why does orforglipron produce less weight loss than tirzepatide?

Orforglipron activates only one receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP). The additional GIP receptor enhances insulin sensitivity and appears to drive more weight loss beyond what GLP-1 alone achieves. Additionally, orforglipron is a partial agonist — it does not fully activate the GLP-1 receptor to the same extent as injectable GLP-1 peptides.

When will orforglipron be available?

Eli Lilly has filed orforglipron for FDA approval in over 40 countries. The US FDA decision for the obesity indication is expected in Q2 2026. It received the FDA Commissioner's National Priority Voucher, which could shorten the review timeline. If approved, it would be among the first non-peptide oral GLP-1 drugs available.

Can I switch from tirzepatide to orforglipron?

Early data supports this. The ATTAIN-MAINTAIN trial showed that patients switching from tirzepatide to orforglipron maintained most of their weight loss, with an average difference of 5.0 kg over 52 weeks. This suggests orforglipron could work as a long-term maintenance option after achieving weight loss on tirzepatide.

What are the side effects of orforglipron compared to tirzepatide?

Both drugs cause similar gastrointestinal side effects: nausea, diarrhea, vomiting, and constipation. Orforglipron has slightly higher nausea (38.8% vs 33%) and vomiting (18.5% vs 10%) rates. Tirzepatide can cause injection site reactions, which orforglipron avoids entirely as a pill. Both drugs see GI side effects improve after the initial dose escalation period.

Sources

Wharton S, et al. "Orforglipron in adults with obesity (ATTAIN-1)." New England Journal of Medicine. 2025. Lilly Press Release
Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038
Eli Lilly. "ATTAIN-MAINTAIN results: Orforglipron maintained weight loss after switching from injectables." Press Release
Rosenstock J, et al. "Orforglipron vs oral semaglutide in type 2 diabetes (ACHIEVE-3)." The Lancet. 2026. Press Release
Eli Lilly. "TRIUMPH-4 results: Retatrutide achieved significant weight loss." Press Release

This article is for informational purposes only and does not constitute medical advice. Orforglipron is an investigational compound that has not been approved by the FDA. Tirzepatide is FDA-approved as Zepbound (obesity) and Mounjaro (type 2 diabetes). Always consult a healthcare provider before starting any medication. This site is not affiliated with Eli Lilly or any pharmaceutical manufacturer.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources